<DOC>
	<DOCNO>NCT01092481</DOCNO>
	<brief_summary>This study design confirm first 3 month oxaliplatin 6 month modify FOLFOX-6 CAPOX treatment inferior 6 month oxaliplatin modify FOLFOX-6 CAPOX treatment term disease free survival patient stage II/III colon cancer .</brief_summary>
	<brief_title>Study Investigating Role Oxaliplatin Duration Modified FOLFOX-6 CAPOX Regimen Adjuvant Colon Cancer Therapy</brief_title>
	<detailed_description>This study design confirm first 3 month oxaliplatin 6 month modify FOLFOX-6 CAPOX treatment inferior 6 month oxaliplatin modify FOLFOX-6 CAPOX treatment term disease free survival patient stage II/III colon cancer . In addition , would like characterize pharmacogenomic profile associate toxicity gene expression profile predict recurrence colon cancer parallel study .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Curatively resect , histologically confirm colon adenocarcinoma AJCC/UICC highrisk stage II , stage III colon cancer Age 18 year old Performance status ( ECOG scale ) : 01 Adequate major organ function Patients sign write informed consent study entry Colon cancer adenocarcinoma Rectal cancer R1 R2 resections Other malignancy within last 5 year Symptomatic peripheral sensory neuropathy Presence serious disease Lactating pregnant woman Fertile woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adjuvant FOLFOX CAPOX Therapy</keyword>
	<keyword>Stage II/III Colon Cancer</keyword>
	<keyword>Adjuvant Therapy</keyword>
</DOC>